Mark Cobbold, SVP of IO Discovery and Cell Therapy Oncology at AstraZeneca, shared a post on LinkedIn:
“It’s always energizing to connect with the IO community. I’m proud of the AstraZeneca team who presented at SITC25 on a range of modalities and their potential role in our strategy to attack cancer from multiple angles.
My colleagues also led sessions in the broader conference program:
- In the Industry Program – Philippe Parone presented on EsoBiotec’s in vivo CAR T-cell therapy technology and Djuro Karanovic delivered a talk on immunity in early-stage disease
- Emily E. Bosco, mentored early career researchers through her faculty role on the SITC ‘Sparkathon’ program
- Zachary Cooper, led a breakout session on collaborating with industry
AstraZeneca’s contributions were recognized with the Champion of SITC – Industry, Catalyst Award. I had the honor of receiving this award on behalf of my colleagues for their contributions to the SITC Cancer Immunotherapy Winter School and the Clinical Practice Guidelines initiatives.
With the growing importance of immunotherapy in cancer treatment, I’m delighted to see our continued support of programs that advance professional development for the IO community. Giovanni Melillo Gordon Moody, Ezogelin Oflazoglu-Gruyters Zachary Cooper,
Next stop: PEGSEurope where we will present on the advanced engineering approaches underpinning our IO programs.
Hope to see you there!”
More posts featuring Mark Cobbold.